




PHARMACEUTICAL 2019

Axsome Therapeutics Inc.
Rank 321 of 363





PHARMACEUTICAL 2019

Axsome Therapeutics Inc.
Rank 321 of 363

The relative strengths and weaknesses of Axsome Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Axsome Therapeutics Inc. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 34% points. The greatest weakness of Axsome Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 116% points.

The company's Economic Capital Ratio, given in the ranking table, is -197%, being 234% points below the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	15,215
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	10,822
Liabilities, Non-Current	3,619
Other Assets	112
Other Compr. Net Income	0
Other Expenses	-2,791
Other Liabilities	0
Other Net Income	-910
Other Revenues	0
Property and Equipment	52
Research and Development	23,495
Selling, General and Administrative Expense	9,352

Output Variable	Value in 1000 USD
Assets	15,379
Liabilities	14,441
Expenses	30,056
Revenues	0
Stockholders Equity	938
Net Income	-30,965
Comprehensive Net Income	-30,965
Economic Capital Ratio	-197%